Skip to main content
Premium Trial:

Request an Annual Quote

EndoChoice to Promote Exagen Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics developer Exagen Diagnostics said today that it has signed up EndoChoice to promote its genomic tests for bowel disorders to gastrointestinal doctors in the US.

EndoChoice, which specializes in gastroenterology, will market Exagen's gene expression tests for diagnosing inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), Albuquerque, NM-based Exagen said in a statement.

Exagen CEO Scott Glenn said that the firm's eXaIBD and eXaIBS tests are sensitive and accurate at distinguishing IBD and IBS from other diseases

Exagen developed these tests using its Coperna computational tool and search engine, which identified genetic signatures associated with IBD and IBS.